menu
    • menu
    [{"orgOrder":0,"company":"CHIRHOCLIN","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Chirhostim","moa":"Secretin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CHIRHOCLIN","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CHIRHOCLIN \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CHIRHOCLIN \/ Undisclosed"},{"orgOrder":0,"company":"CHIRHOCLIN","sponsor":"CHIRHOCLIN","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Secretin","moa":"Secretin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"CHIRHOCLIN","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHIRHOCLIN \/ CHIRHOCLIN","highestDevelopmentStatusID":"10","companyTruncated":"CHIRHOCLIN \/ CHIRHOCLIN"},{"orgOrder":0,"company":"CHIRHOCLIN","sponsor":"Dartmouth-Hitchcock Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Secretin","moa":"Secretin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"CHIRHOCLIN","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center"},{"orgOrder":0,"company":"CHIRHOCLIN","sponsor":"Dartmouth-Hitchcock Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Secretin","moa":"Secretin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CHIRHOCLIN","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center"}]

    Find Clinical Drug Pipeline Developments & Deals by CHIRHOCLIN

    Menu

    CHIRHOCLIN

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Secretin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Orlando Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

                            Details : Human Secretin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Abdominal Pain.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : Human Secretin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Orlando Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secretin for Acute Pancreatitis

                            Details : Secretin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatitis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 27, 2018

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secretin Infusion for Pain Due to Chronic Pancreatitis

                            Details : Secretin is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatitis, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 23, 2010

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            CHIRHOCLIN

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chirhostim

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas...

                            Details : Chirhostim is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Diseases.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 16, 2010

                            Lead Product(s) : Chirhostim

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth